Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Evaluating Reflexology Impact on Breast Cancer RT-Related Anxiety, Pain

October 17, 2024
By Heather Zinkin, MD
Commentary
Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.

CancerNetwork® spoke with Heather Zinkin, MD, chief of radiation medicine at Huntington Hospital of the Northwell Health Cancer Institute, about how reflexology was utilized in patients with breast cancer undergoing radiation therapy and how the efficacy of the intervention was assessed. She discussed this methodology in the context of a study she presented at the 2024 American Society of Radiation Oncology (ASTRO) Annual Meeting.

Zinkin began by highlighting the inclusion of a holistic nurse for a full workday every week, which was funded by the Northwell Center for Wellness and Integrative Medicine. She further explained that patients were offered a complimentary 15-minute session with the nurse for up to 5 weeks in a converted exam room which served as a quiet, meditative space.

Zinkin further outlined the process, whereby patients chose which portion of the body they wanted to receive reflexology, which was supplemented with mindfulness. She then stated that the impact of reflexology sessions was assessed through anonymous pre- and post-intervention stress thermometer surveys, which measured patient-reported energy, anxiety, and pain.

The study assessed 560 patient encounters from April 2022 through December 2023 to evaluate the impact of reflexology on patient-reported levels of stress, pain, and energy. Findings from the study showed that stress and pain were reduced by 40.0% and 24.0%, respectively, and that energy increased by 33.3%. Additionally, improvement in patient well-being overall was reported to have increased by 33.3% (P < .0001).

Transcript:

We were fortunately able to obtain funding from Northwell Center for Wellness and Integrative Medicine for a holistic nurse from their practice to come to our office for a full workday every week. Then we were able to offer every [patient with] breast cancer who was under treatment––receiving radiation therapy––a complimentary 15-minute session with her for up to 5 weeks. We converted one of our exam rooms into a quiet, meditative space with dim lighting, flameless candles, and some soft music. Women were able to choose what part of the body they preferred, whether it be their hands, their feet, or their neck, and they were offered 15 minutes of reflexology, including some mindfulness. Each patient was asked anonymously to complete a stress thermometer survey prior to and after each session so that we could evaluate the response to each therapy. We looked at various metrics, including energy, anxiety, and pain.

Reference

Zinkin HD, Kostroff K, Dimisa D, et al. Reflexology as an integrative approach to improve stress, energy, and pain in women receiving radiotherapy for breast cancer. Int J Radiat Oncol. 2024;120(suppl 2):e423. doi:10.1016/j.ijrobp.2024.07.944

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Related Content

A statistically significant difference was observed between the 2 groups in patients who received second-line therapy.

Cisplatin/Carboplatin Plus Etoposide Yield Similar Real-World Efficacy in ES-SCLC

Tim Cortese
September 16th 2025
Article

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 16th 2025
Podcast

Numerically higher ORRs were reported in those who received treatment in the second line vs third line, in those with a CTFI of 90 days or more, and those without CNS metastasis.

Lurbinectedin Yields Responses in Various ES-SCLC Subgroups

Tim Cortese
September 16th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 16th 2025
Podcast

All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.

Surufatinib Combo Displays Promising Efficacy in Frontline ES-SCLC

Roman Fabbricatore
September 16th 2025
Article

The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 16th 2025
Article
Related Content

A statistically significant difference was observed between the 2 groups in patients who received second-line therapy.

Cisplatin/Carboplatin Plus Etoposide Yield Similar Real-World Efficacy in ES-SCLC

Tim Cortese
September 16th 2025
Article

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 16th 2025
Podcast

Numerically higher ORRs were reported in those who received treatment in the second line vs third line, in those with a CTFI of 90 days or more, and those without CNS metastasis.

Lurbinectedin Yields Responses in Various ES-SCLC Subgroups

Tim Cortese
September 16th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 16th 2025
Podcast

All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.

Surufatinib Combo Displays Promising Efficacy in Frontline ES-SCLC

Roman Fabbricatore
September 16th 2025
Article

The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 16th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.